TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Eligible age

18–80 yrs

Accepts

All genders

Locations

31 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

Sponsor: 89bio, Inc.

Where it's recruiting

Alabama

Birmingham

Arizona

Chandler · Flagstaff · Glendale · Tucson

Arkansas

Conway · Little Rock · North Little Rock

California

Canoga Park · Coronado · Escondido · Fountain Valley

Colorado

Colorado Springs · Littleton

Florida

Brandon · Clermont · Fort Myers · Hialeah Gardens

Georgia

Athens · Dalton · Marietta

Illinois

Chicago

Indiana

Hammond · New Albany · South Bend

Iowa

Iowa City

Kansas

Topeka

Louisiana

Covington · Houma · Lake Charles · Marrero

Source: ClinicalTrials.gov · NCT06318169 · last updated 2026-06-04